Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of SHR-A2102 for Injection in Gynecologic Malignancies
CTR20243945Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-A2102 in gynecological cancer, sponsored by Hengrui Therapeutics. Started Dec 2024; status: active.
02
Drugs
SHR-A2102
03
Conditions
gynecological cancer
Beyond the preview
Go deeper on CTR20243945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243945.